Olaparib tops chemotherapy for quality of life in metastatic breast cancer

  • Robson M & al.
  • Eur J Cancer
  • 22 Aug 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Olaparib was superior to chemotherapy on global health status/QoL score (vs baseline) in a phase 3 trial of patients with germline BRCA mutation and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Why this matters

  • Quality of life is crucial in patients with poor prognosis for survival.

Study design

  • Multicenter randomized OlympiAD trial (n=302) comparing olaparib monotherapy (300 mg twice daily) vs single-agent chemotherapy treatment of physician's choice (capecitabine, vinorelbine, or eribulin).
  • Primary outcome was mean change from baseline in the 2-item global health status/QoL score based on the patient-completed EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30-item module).
  • Funding: AstraZeneca; MSD.

Key results

  • Olaparib yielded a 7.5-point greater mean change from baseline in global health status/QoL score vs chemotherapy (3.9±1.2 standard deviation [SD] vs −3.6±2.2 SD; P=.0035).
  • A higher proportion of olaparib-treated patients achieved best overall response of improvement in global health status/QoL (33.7% vs 13.4%).
  • Olaparib-treated patients reported less deterioration (11.7% vs 20.6%).
  • The only worse outcome with olaparib was nausea/vomiting symptom score (across all visits vs baseline).

Limitations

  • Open-label design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit